Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTOVGLPG)

• DOT Name: Actin, alpha skeletal muscle (ACTA1)
• Synonyms: EC 3.6.4.-; Alpha-actin-1
• Gene Name: ACTA1
• Related Disease:
  Alpha-actinopathy
  Myofibrillar myopathy
  Nemaline myopathy 3
  Obsolete congenital myopathy with excess of thin filaments
  Autoimmune hepatitis
  Breast cancer
  Breast carcinoma
  Congenital muscular dystrophy
  Congenital myopathy 2c, severe infantile, autosomal dominant
  Cryptococcal meningitis
  Dilated cardiomyopathy
  Distal myopathy
  Hepatitis C virus infection
  Listeriosis
  Myopathy
  Neoplasm
  Polycystic ovarian syndrome
  Rigid spine muscular dystrophy 1
  Scapuloperoneal myopathy
  Spinal muscular atrophy, type 1
  Female hypogonadism
  Head-neck squamous cell carcinoma
  Respiratory failure
  Childhood-onset nemaline myopathy
  Congenital fiber-type disproportion myopathy
  Intermediate nemaline myopathy
  Progressive scapulohumeroperoneal distal myopathy
  Rigid spine syndrome
  Severe congenital nemaline myopathy
  Typical nemaline myopathy
  Zebra body myopathy
  Amyotrophic lateral sclerosis
  Bone Paget disease
  Inclusion body myopathy with Paget disease of bone and frontotemporal dementia
  Asthma
  Atrial septal defect
  Cap myopathy
  Congenital myopathy
  Fetal growth restriction
  GNE myopathy
  Hypertrophic cardiomyopathy
  Neuromuscular disease
  Ventricular fibrillation
  X-linked myopathy with excessive autophagy
• UniProt ID: ACTS_HUMAN
• PDB ID: 7RNS; 7RNU; 7RNV
• EC Number: 3.6.4.-
• Pfam ID: PF00022
• Sequence:
  MCDEDETTALVCDNGSGLVKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEA
  QSKRGILTLKYPIEHGIITNWDDMEKIWHHTFYNELRVAPEEHPTLLTEAPLNPKANREK
  MTQIMFETFNVPAMYVAIQAVLSLYASGRTTGIVLDSGDGVTHNVPIYEGYALPHAIMRL
  DLAGRDLTDYLMKILTERGYSFVTTAEREIVRDIKEKLCYVALDFENEMATAASSSSLEK
  SYELPDGQVITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDIDIRKDLYANNV
  MSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWIT
  KQEYDEAGPSIVHRKCF
• Function: Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells.
• KEGG Pathway:
  Motor proteins (hsa04814)
  Cytoskeleton in muscle cells (hsa04820)
• Reactome Pathway: Striated Muscle Contraction (R-HSA-390522)

Molecular Interaction Atlas (MIA) of This DOT

44 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Alpha-actinopathy	DISE0PV2	Definitive	Autosomal recessive	[1]
Myofibrillar myopathy	DISF24LW	Definitive	Genetic Variation	[2]
Nemaline myopathy 3	DISAUOU5	Definitive	Semidominant	[3]
Obsolete congenital myopathy with excess of thin filaments	DIS2FXY9	Definitive	Semidominant	[4]
Autoimmune hepatitis	DISOX03Q	Strong	Altered Expression	[5]
Breast cancer	DIS7DPX1	Strong	Altered Expression	[6]
Breast carcinoma	DIS2UE88	Strong	Altered Expression	[6]
Congenital muscular dystrophy	DISKY7OY	Strong	Genetic Variation	[7]
Congenital myopathy 2c, severe infantile, autosomal dominant	DISGO90Z	Strong	Autosomal dominant	[8]
Cryptococcal meningitis	DIS1LBC6	Strong	Biomarker	[9]
Dilated cardiomyopathy	DISX608J	Strong	Biomarker	[10]
Distal myopathy	DIS7F5R0	Strong	Genetic Variation	[11]
Hepatitis C virus infection	DISQ0M8R	Strong	Biomarker	[12]
Listeriosis	DISKMQBM	Strong	Biomarker	[13]
Myopathy	DISOWG27	Strong	Biomarker	[14]
Neoplasm	DISZKGEW	Strong	Altered Expression	[6]
Polycystic ovarian syndrome	DISZ2BNG	Strong	Genetic Variation	[15]
Rigid spine muscular dystrophy 1	DISHZE8T	Strong	GermlineCausalMutation	[7]
Scapuloperoneal myopathy	DIS5AULW	Strong	Genetic Variation	[16]
Spinal muscular atrophy, type 1	DISYCWUG	Strong	Altered Expression	[17]
Female hypogonadism	DISWASB4	moderate	Genetic Variation	[18]
Head-neck squamous cell carcinoma	DISF7P24	moderate	Biomarker	[19]
Respiratory failure	DISVMYJO	moderate	Genetic Variation	[20]
Childhood-onset nemaline myopathy	DIST7MSL	Supportive	Autosomal dominant	[21]
Congenital fiber-type disproportion myopathy	DISU9T2M	Supportive	Autosomal dominant	[22]
Intermediate nemaline myopathy	DISMJ4LI	Supportive	Autosomal dominant	[21]
Progressive scapulohumeroperoneal distal myopathy	DISRFENG	Supportive	Autosomal dominant	[16]
Rigid spine syndrome	DISA1BDS	Supportive	Autosomal recessive	[7]
Severe congenital nemaline myopathy	DISJR7WP	Supportive	Autosomal recessive	[21]
Typical nemaline myopathy	DISY1645	Supportive	Autosomal dominant	[21]
Zebra body myopathy	DISMCSNK	Supportive	Unknown	[23]
Amyotrophic lateral sclerosis	DISF7HVM	Disputed	Altered Expression	[24]
Bone Paget disease	DISIPS4V	Disputed	Altered Expression	[24]
Inclusion body myopathy with Paget disease of bone and frontotemporal dementia	DISK4S94	Disputed	Altered Expression	[24]
Asthma	DISW9QNS	Limited	Biomarker	[25]
Atrial septal defect	DISJT76B	Limited	Biomarker	[26]
Cap myopathy	DIS4S4WQ	Limited	Genetic Variation	[27]
Congenital myopathy	DISLSK9G	Limited	Genetic Variation	[28]
Fetal growth restriction	DIS5WEJ5	Limited	Biomarker	[29]
GNE myopathy	DIS73X4W	Limited	Biomarker	[30]
Hypertrophic cardiomyopathy	DISQG2AI	Limited	Biomarker	[10]
Neuromuscular disease	DISQTIJZ	Limited	CausalMutation	[31]
Ventricular fibrillation	DIS7IN76	Limited	Biomarker	[32]
X-linked myopathy with excessive autophagy	DIS1AFQH	Limited	Genetic Variation	[14]

3 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate increases the methylation of Actin, alpha skeletal muscle (ACTA1).	[33]
Fulvestrant	DM0YZC6	Approved	Fulvestrant increases the methylation of Actin, alpha skeletal muscle (ACTA1).	[44]
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene increases the methylation of Actin, alpha skeletal muscle (ACTA1).	[49]

23 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Ciclosporin	DMAZJFX	Approved	Ciclosporin decreases the expression of Actin, alpha skeletal muscle (ACTA1).	[34]
Doxorubicin	DMVP5YE	Approved	Doxorubicin decreases the expression of Actin, alpha skeletal muscle (ACTA1).	[35]
Cupric Sulfate	DMP0NFQ	Approved	Cupric Sulfate increases the expression of Actin, alpha skeletal muscle (ACTA1).	[36]
Ivermectin	DMDBX5F	Approved	Ivermectin decreases the expression of Actin, alpha skeletal muscle (ACTA1).	[37]
Quercetin	DM3NC4M	Approved	Quercetin increases the expression of Actin, alpha skeletal muscle (ACTA1).	[38]
Hydrogen peroxide	DM1NG5W	Approved	Hydrogen peroxide affects the expression of Actin, alpha skeletal muscle (ACTA1).	[39]
Calcitriol	DM8ZVJ7	Approved	Calcitriol increases the expression of Actin, alpha skeletal muscle (ACTA1).	[40]
Vorinostat	DMWMPD4	Approved	Vorinostat increases the expression of Actin, alpha skeletal muscle (ACTA1).	[41]
Testosterone	DM7HUNW	Approved	Testosterone increases the expression of Actin, alpha skeletal muscle (ACTA1).	[40]
Triclosan	DMZUR4N	Approved	Triclosan decreases the expression of Actin, alpha skeletal muscle (ACTA1).	[42]
Carbamazepine	DMZOLBI	Approved	Carbamazepine affects the expression of Actin, alpha skeletal muscle (ACTA1).	[43]
Folic acid	DMEMBJC	Approved	Folic acid decreases the expression of Actin, alpha skeletal muscle (ACTA1).	[45]
Cytarabine	DMZD5QR	Approved	Cytarabine increases the expression of Actin, alpha skeletal muscle (ACTA1).	[46]
Etoposide	DMNH3PG	Approved	Etoposide decreases the expression of Actin, alpha skeletal muscle (ACTA1).	[47]
Diclofenac	DMPIHLS	Approved	Diclofenac affects the expression of Actin, alpha skeletal muscle (ACTA1).	[43]
Mitoxantrone	DMM39BF	Approved	Mitoxantrone decreases the expression of Actin, alpha skeletal muscle (ACTA1).	[35]
Daunorubicin	DMQUSBT	Approved	Daunorubicin decreases the expression of Actin, alpha skeletal muscle (ACTA1).	[35]
Urethane	DM7NSI0	Phase 4	Urethane decreases the expression of Actin, alpha skeletal muscle (ACTA1).	[48]
SNDX-275	DMH7W9X	Phase 3	SNDX-275 decreases the expression of Actin, alpha skeletal muscle (ACTA1).	[41]
Leflunomide	DMR8ONJ	Phase 1 Trial	Leflunomide increases the expression of Actin, alpha skeletal muscle (ACTA1).	[50]
PMID28460551-Compound-2	DM4DOUB	Patented	PMID28460551-Compound-2 decreases the expression of Actin, alpha skeletal muscle (ACTA1).	[51]
EMODIN	DMAEDQG	Terminated	EMODIN decreases the expression of Actin, alpha skeletal muscle (ACTA1).	[52]
Bisphenol A	DM2ZLD7	Investigative	Bisphenol A decreases the expression of Actin, alpha skeletal muscle (ACTA1).	[53]

References

• [1] Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
• [2] New aspects of myofibrillar myopathies.Curr Opin Neurol. 2016 Oct;29(5):628-34. doi: 10.1097/WCO.0000000000000357.
• [3] Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
• [4] Mutations in the skeletal muscle alpha-actin gene in patients with actin myopathy and nemaline myopathy. Nat Genet. 1999 Oct;23(2):208-12. doi: 10.1038/13837.
• [5] Foxp3?Treg Cells Are Associated with Pathological Process of Autoimmune Hepatitis by Activating Methylation Modification in Autoimmune Hepatitis Patients.Med Sci Monit. 2019 Aug 18;25:6204-6212. doi: 10.12659/MSM.915408.
• [6] High ASMA(+) Fibroblasts and Low Cytoplasmic HMGB1(+) Breast Cancer Cells Predict PoorPrognosis.Clin Breast Cancer. 2017 Oct;17(6):441-452.e2. doi: 10.1016/j.clbc.2017.04.007. Epub 2017 Apr 21.
• [7] Recessive ACTA1 variant causes congenital muscular dystrophy with rigid spine. Eur J Hum Genet. 2015 Jun;23(6):883-6. doi: 10.1038/ejhg.2014.169. Epub 2014 Sep 3.
• [8] His(73), often methylated, is an important structural determinant for actin. A mutagenic analysis of HIS(73) of yeast actin. J Biol Chem. 1999 Dec 24;274(52):37443-9. doi: 10.1074/jbc.274.52.37443.
• [9] One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi.Clin Infect Dis. 2020 Jan 16;70(3):521-524. doi: 10.1093/cid/ciz454.
• [10] Nemaline myopathy with dilated cardiomyopathy in childhood.Pediatrics. 2013 Jun;131(6):e1986-90. doi: 10.1542/peds.2012-1139. Epub 2013 May 6.
• [11] Autosomal dominant distal myopathy with nemaline rods due to p.Glu197Asp mutation in ACTA1.Neuromuscul Disord. 2019 Mar;29(3):247-250. doi: 10.1016/j.nmd.2018.12.001. Epub 2018 Dec 10.
• [12] Assessment of the Prevalence of Non-Organ-Specific Autoantibodies in Egyptian Patients with HCV.Immunol Invest. 2020 Aug;49(6):676-686. doi: 10.1080/08820139.2019.1699108. Epub 2019 Dec 10.
• [13] RAPD- and actA gene-typing of Listeria monocytogenes isolates of human listeriosis, the intestinal contents of cows and beef.Microbiol Immunol. 2001;45(2):127-33. doi: 10.1111/j.1348-0421.2001.tb01280.x.
• [14] ACTA1-myopathy with prominent finger flexor weakness and rimmed vacuoles.Neuromuscul Disord. 2019 May;29(5):388-391. doi: 10.1016/j.nmd.2019.02.012. Epub 2019 Mar 2.
• [15] Association of vitamin D receptor gene polymorphisms with polycystic ovary syndrome among Indian women.Indian J Med Res. 2015 Sep;142(3):276-85. doi: 10.4103/0971-5916.166587.
• [16] Association of a Novel ACTA1 Mutation With a Dominant Progressive Scapuloperoneal Myopathy in an Extended Family. JAMA Neurol. 2015 Jun;72(6):689-98. doi: 10.1001/jamaneurol.2015.37.
• [17] Epidemiological data on Werdnig-Hoffmann disease in Germany (West-Thringen).Hum Genet. 1993 Apr;91(3):295-7. doi: 10.1007/BF00218278.
• [18] Association of polymorphisms in microRNA machinery genes (DROSHA, DICER1, RAN, and XPO5) with risk of idiopathic primary ovarian insufficiency in Korean women.Menopause. 2013 Oct;20(10):1067-73. doi: 10.1097/GME.0b013e3182883907.
• [19] Identification of SERPINE1, PLAU and ACTA1 as biomarkers of head and neck squamous cell carcinoma based on integrated bioinformatics analysis.Int J Clin Oncol. 2019 Sep;24(9):1030-1041. doi: 10.1007/s10147-019-01435-9. Epub 2019 Apr 1.
• [20] Actin mutations are one cause of congenital fibre type disproportion.Ann Neurol. 2004 Nov;56(5):689-94. doi: 10.1002/ana.20260.
• [21] Clinical Practice Guidelines for Rare Diseases: The Orphanet Database. PLoS One. 2017 Jan 18;12(1):e0170365. doi: 10.1371/journal.pone.0170365. eCollection 2017.
• [22] Congenital Fiber-Type Disproportion C RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY. 2007 Jan 12 [updated 2013 Apr 11]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews(?) [Internet]. Seattle (WA): University of Washington, Seattle; 1993C2024.
• [23] Zebra body myopathy is caused by a mutation in the skeletal muscle actin gene (ACTA1). Neuromuscul Disord. 2015 May;25(5):388-91. doi: 10.1016/j.nmd.2015.02.003. Epub 2015 Feb 14.
• [24] VCP maintains lysosomal homeostasis and TFEB activity in differentiated skeletal muscle.Autophagy. 2019 Jun;15(6):1082-1099. doi: 10.1080/15548627.2019.1569933. Epub 2019 Jan 29.
• [25] Association of defensin beta-1 gene polymorphisms with asthma.J Allergy Clin Immunol. 2005 Feb;115(2):252-8. doi: 10.1016/j.jaci.2004.11.013.
• [26] Reduced ACTC1 expression might play a role in the onset of congenital heart disease by inducing cardiomyocyte apoptosis.Circ J. 2010 Nov;74(11):2410-8. doi: 10.1253/circj.cj-10-0234. Epub 2010 Oct 15.
• [27] Combined cap disease and nemaline myopathy in the same patient caused by an autosomal dominant mutation in the TPM3 gene.Neuromuscul Disord. 2013 Dec;23(12):992-7. doi: 10.1016/j.nmd.2013.07.003. Epub 2013 Oct 2.
• [28] Prevalence and phenotypes of congenital myopathy due to -actin 1 gene mutations.Muscle Nerve. 2016 Mar;53(3):388-93. doi: 10.1002/mus.24765. Epub 2015 Aug 13.
• [29] The impact of placental massive perivillous fibrin deposition on neonatal outcome in pregnancies complicated by fetal growth restriction.Placenta. 2019 Nov;87:46-52. doi: 10.1016/j.placenta.2019.09.007. Epub 2019 Sep 17.
• [30] Evidence for a dominant-negative effect in ACTA1 nemaline myopathy caused by abnormal folding, aggregation and altered polymerization of mutant actin isoforms.Hum Mol Genet. 2004 Aug 15;13(16):1727-43. doi: 10.1093/hmg/ddh185. Epub 2004 Jun 15.
• [31] Structure of the F-actin-tropomyosin complex.Nature. 2015 Mar 5;519(7541):114-7. doi: 10.1038/nature14033. Epub 2014 Dec 1.
• [32] Correlation of alpha-skeletal actin expression, ventricular fibrosis and heart function with the degree of pressure overload cardiac hypertrophy in rats.Exp Physiol. 2006 May;91(3):571-80. doi: 10.1113/expphysiol.2005.032607. Epub 2006 Feb 1.
• [33] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [34] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [35] Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment. Arch Toxicol. 2016 Nov;90(11):2763-2777.
• [36] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [37] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [38] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [39] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [40] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [41] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [42] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [43] Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
• [44] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [45] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [46] Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol. 2011 Apr;162(8):1743-56.
• [47] Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells. Arch Toxicol. 2018 Apr;92(4):1507-1524.
• [48] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [49] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [50] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [51] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [52] Gene expression alteration during redox-dependent enhancement of arsenic cytotoxicity by emodin in HeLa cells. Cell Res. 2005 Jul;15(7):511-22.
• [53] Isobaric tags for relative and absolute quantitation-based proteomics analysis of the effect of ginger oil on bisphenol A-induced breast cancer cell proliferation. Oncol Lett. 2021 Feb;21(2):101. doi: 10.3892/ol.2020.12362. Epub 2020 Dec 8.